perindopril Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 2108 82834-16-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • perindopril
  • perindopril erbumine
  • perindopril arginine
An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.
  • Molecular weight: 368.47
  • Formula: C19H32N2O5
  • CLOGP: 1.21
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -2.48
  • ROTB: 9

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.60 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1993 FDA SYMPLMED PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 556.30 52.14 153 835 27969 2329128
Hyponatraemia 348.32 52.14 91 897 13234 2343863
Hyperkalaemia 278.88 52.14 65 923 5828 2351269
Hypotension 276.35 52.14 93 895 32343 2324754
Fall 179.18 52.14 75 913 47024 2310073
Metabolic acidosis 175.37 52.14 45 943 5953 2351144
Cough 150.39 52.14 60 928 33057 2324040
Conjoined twins 131.32 52.14 16 972 12 2357085
Lactic acidosis 122.11 52.14 33 955 5297 2351800
Confusional state 116.86 52.14 46 942 24298 2332799
Angioedema 115.86 52.14 35 953 8361 2348736
Intentional overdose 109.59 52.14 36 952 11285 2345812
Tinnitus 104.61 52.14 29 959 5106 2351991
Inappropriate antidiuretic hormone secretion 101.04 52.14 24 964 2285 2354812
Bradycardia 97.60 52.14 32 956 9949 2347148
Intestinal malrotation 95.69 52.14 13 975 40 2357057
Overdose 93.24 52.14 37 951 19870 2337227
Vomiting 92.79 52.14 55 933 71547 2285550
Urachal abnormality 90.99 52.14 11 977 7 2357090
Labile hypertension 90.50 52.14 13 975 66 2357031
Persistent cloaca 88.30 52.14 11 977 12 2357085
Atrial fibrillation 87.52 52.14 32 956 13736 2343361
Congenital bladder anomaly 86.14 52.14 11 977 17 2357080
Orthostatic hypotension 85.88 52.14 22 966 2857 2354240
Lower respiratory tract infection 85.11 52.14 25 963 5399 2351698
Malaise 80.61 52.14 46 942 55539 2301558
Coma 80.36 52.14 27 961 9029 2348068
Renal failure 80.33 52.14 32 956 17317 2339780
Hypokalaemia 79.89 52.14 28 960 10626 2346471
Hyperlactacidaemia 75.50 52.14 14 974 395 2356702
Dehydration 72.58 52.14 32 956 22263 2334834
General physical health deterioration 72.16 52.14 28 960 14111 2342986
Coma scale abnormal 71.56 52.14 15 973 803 2356294
Body mass index decreased 70.78 52.14 10 978 44 2357053
Product packaging confusion 69.90 52.14 10 978 49 2357048
Normochromic normocytic anaemia 67.37 52.14 14 974 718 2356379
Hypertension 66.31 52.14 32 956 27329 2329768
Labelled drug-drug interaction medication error 64.55 52.14 15 973 1293 2355804
Chest pain 62.46 52.14 31 957 28106 2328991
Shock 56.43 52.14 17 971 3987 2353110
Suicide attempt 56.30 52.14 22 966 11260 2345837
Limb malformation 55.13 52.14 9 979 117 2356980
Hypoglycaemia 55.04 52.14 20 968 8387 2348710
Allergic reaction to excipient 52.87 52.14 8 980 61 2357036
Toxicity to various agents 52.43 52.14 29 959 32725 2324372

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 686.91 49.55 226 1086 34718 1710751
Hyperkalaemia 276.36 49.55 82 1230 8465 1737004
Hypotension 235.43 49.55 100 1212 29554 1715915
Dyspnoea 210.23 49.55 110 1202 51949 1693520
Hyponatraemia 196.37 49.55 64 1248 8936 1736533
Fall 177.18 49.55 80 1232 27134 1718335
Venous pressure jugular increased 171.77 49.55 26 1286 77 1745392
Metabolic acidosis 170.47 49.55 51 1261 5351 1740118
Renal failure 156.44 49.55 67 1245 19950 1725519
Atrial fibrillation 153.35 49.55 61 1251 15050 1730419
Cardiac murmur 133.77 49.55 31 1281 1191 1744278
Cholestasis 125.92 49.55 37 1275 3628 1741841
Cough 123.13 49.55 56 1256 19141 1726328
Lactic acidosis 121.86 49.55 39 1273 5090 1740379
Left ventricular dysfunction 118.21 49.55 28 1284 1183 1744286
Oedema peripheral 117.78 49.55 51 1261 15499 1729970
Cardiac failure 117.73 49.55 48 1264 12554 1732915
Coma scale abnormal 97.30 49.55 21 1291 578 1744891
Drug interaction 94.83 49.55 53 1259 27905 1717564
Ventricular tachycardia 94.76 49.55 30 1282 3768 1741701
Dizziness 89.79 49.55 55 1257 34306 1711163
Dermatomyositis 88.80 49.55 17 1295 251 1745218
Dyspnoea exertional 88.02 49.55 29 1283 4132 1741337
Hepatocellular injury 86.75 49.55 27 1285 3204 1742265
Ejection fraction decreased 82.92 49.55 24 1288 2221 1743248
Respiratory failure 82.47 49.55 39 1273 14466 1731003
Hypoglycaemia 81.61 49.55 33 1279 8405 1737064
Oedema 80.60 49.55 31 1281 6917 1738552
Hypertension 77.28 49.55 41 1271 19407 1726062
Eosinophilia 76.26 49.55 25 1287 3502 1741967
Hypokalaemia 75.93 49.55 29 1283 6345 1739124
Dissociation 75.70 49.55 15 1297 267 1745202
Alveolitis 72.30 49.55 15 1297 339 1745130
Blood creatinine increased 71.67 49.55 35 1277 13911 1731558
Paraesthesia 71.57 49.55 32 1280 10419 1735050
Angioedema 70.71 49.55 31 1281 9633 1735836
Mitral valve incompetence 68.33 49.55 20 1292 1922 1743547
Tricuspid valve incompetence 67.51 49.55 18 1294 1228 1744241
Diastolic dysfunction 66.64 49.55 15 1297 502 1744967
Anaemia 66.38 49.55 43 1269 29414 1716055
Contraindicated product administered 64.88 49.55 18 1294 1426 1744043
Intentional overdose 63.96 49.55 27 1285 7643 1737826
Renal tubular necrosis 62.31 49.55 19 1293 2100 1743369
Abnormal loss of weight 60.94 49.55 14 1298 514 1744955
Acute respiratory distress syndrome 60.30 49.55 21 1291 3530 1741939
Overdose 60.10 49.55 33 1279 16668 1728801
Rash maculo-papular 59.44 49.55 21 1291 3682 1741787
Left ventricular hypertrophy 59.19 49.55 15 1297 837 1744632
Sinus tachycardia 58.98 49.55 19 1293 2513 1742956
Crystalluria 58.49 49.55 10 1302 74 1745395
Melaena 55.95 49.55 22 1290 5188 1740281
Left ventricular failure 51.98 49.55 13 1299 687 1744782
Feeling abnormal 51.31 49.55 26 1286 11140 1734329
Syncope 50.95 49.55 28 1284 14141 1731328
Hypoosmolar state 50.49 49.55 7 1305 8 1745461
Hypoxia 49.71 49.55 21 1291 5942 1739527
Loss of consciousness 49.67 49.55 28 1284 14847 1730622

Pharmacologic Action:

SourceCodeDescription
ATC C09AA04 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA04 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
ATC C09BB04 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
ATC C09BX01 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors, other combinations
ATC C09BX02 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors, other combinations
ATC C09BX04 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors, other combinations
ATC C10BX11 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
ATC C10BX12 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
ATC C10BX13 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
ATC C10BX14 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
ATC C10BX15 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:35674 antihypertensive agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Myocardial Infarction Prevention indication
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Hyperkalemia contraindication 14140009
Acute cerebrovascular insufficiency contraindication 29322000
Angioedema contraindication 41291007 DOID:1558
Low blood pressure contraindication 45007003
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.23 acidic
pKa2 6.38 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
14MG PRESTALIA ADHERA N205003 Jan. 21, 2015 RX TABLET ORAL 6696481 April 15, 2023 TREATMENT OF HYPERTENSION
3.5MG PRESTALIA ADHERA N205003 Jan. 21, 2015 RX TABLET ORAL 6696481 April 15, 2023 TREATMENT OF HYPERTENSION
7MG PRESTALIA ADHERA N205003 Jan. 21, 2015 RX TABLET ORAL 6696481 April 15, 2023 TREATMENT OF HYPERTENSION
14MG PRESTALIA ADHERA N205003 Jan. 21, 2015 RX TABLET ORAL 7846961 Oct. 5, 2029 TREATMENT OF HYPERTENSION
3.5MG PRESTALIA ADHERA N205003 Jan. 21, 2015 RX TABLET ORAL 7846961 Oct. 5, 2029 TREATMENT OF HYPERTENSION
7MG PRESTALIA ADHERA N205003 Jan. 21, 2015 RX TABLET ORAL 7846961 Oct. 5, 2029 TREATMENT OF HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 8.82 CHEMBL CHEMBL

External reference:

IDSource
4021179 VUID
N0000148627 NUI
C0136123 UMLSCUI
D00624 KEGG_DRUG
1964X464OJ UNII
107133-36-8 SECONDARY_CAS_RN
5987 INN_ID
129486004 SNOMEDCT_US
4021179 VANDF
004018 NDDF
54552 RXNORM
372916001 SNOMEDCT_US
d04440 MMSL
DB00790 DRUGBANK_ID
CHEMBL1581 ChEMBL_ID
CHEMBL1200343 ChEMBL_ID
X94 PDB_CHEM_ID
CHEBI:8024 CHEBI
CHEMBL1201368 ChEMBL_ID
D020913 MESH_DESCRIPTOR_UI
C053500 MESH_SUPPLEMENTAL_RECORD_UI
CHEMBL3544986 ChEMBL_ID
107807 PUBCHEM_CID
6367 IUPHAR_LIGAND_ID
DB14213 DRUGBANK_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0110 TABLET 2 mg ORAL ANDA 17 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0111 TABLET 4 mg ORAL ANDA 17 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0112 TABLET 8 mg ORAL ANDA 17 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1919 TABLET 4 mg ORAL NDA 18 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1920 TABLET 8 mg ORAL NDA 18 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 10135-599 TABLET 4 mg ORAL NDA 18 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 10135-600 TABLET 8 mg ORAL NDA 18 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 65862-286 TABLET 2 mg ORAL ANDA 17 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 65862-287 TABLET 4 mg ORAL ANDA 17 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 65862-288 TABLET 8 mg ORAL ANDA 17 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 68180-235 TABLET 2 mg ORAL ANDA 12 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 68180-236 TABLET 4 mg ORAL ANDA 12 sections
Perindopril Erbumine HUMAN PRESCRIPTION DRUG LABEL 1 68180-237 TABLET 8 mg ORAL ANDA 12 sections
Prestalia HUMAN PRESCRIPTION DRUG LABEL 2 72931-010 TABLET 3.50 mg ORAL NDA 18 sections
Prestalia HUMAN PRESCRIPTION DRUG LABEL 2 72931-011 TABLET 7 mg ORAL NDA 18 sections
Prestalia HUMAN PRESCRIPTION DRUG LABEL 2 72931-012 TABLET 14 mg ORAL NDA 18 sections
Aceon HUMAN PRESCRIPTION DRUG LABEL 1 76234-002 TABLET 8 mg ORAL NDA 19 sections